Stratification of primary tumors according to a strong CD3+ infiltrate and a high PD-1/PD-L1 expression might identify ovarian cancer patients who are responsive to a combination of platinum-based chemotherapy with checkpoint-inhibitors [30,31]. The gene discussed is PDCD1; the disease is ovarian carcinoma.